Healthcare · Risk & Compliance
Automate Compliance Operations in Biotechnology with Audit-Ready AI
We design, build, and run AI-native compliance operations for biotech founders, clinical operations teams, business development leaders, and scientific program managers. This page describes the engagement: scope, pricing, timeline, controls, and the KPIs we commit to.
Early access: we work with a small first cohort. Engagements are scoped, priced, and shipped end-to-end by our team — not referred to third parties.
In one sentence
AI-native compliance operations for biotechnology is a phased engagement (Discovery 2 weeks → Build 8 weeks → Run continuous (4-week initial stabilization)) that ships a production workflow on top of ELN and LIMS, moves audit readiness by +38 pts against the biotechnology baseline, and is operated under risk & compliance governance from day one.
Key facts
- Industry
- Biotechnology
- Use case
- Compliance Operations
- Intent cluster
- Risk & Compliance
- Primary KPI
- audit readiness, control failure rate, review cycle time, and remediation backlog
- Top benchmark
- Audit-log completeness: 62% → 100% (+38 pts)
- Systems integrated
- ELN, LIMS, clinical trial systems
- Buyer
- biotech founders, clinical operations teams, business development leaders, and scientific program managers
- Risk lens
- scientific validity, IP protection, trial documentation, privacy, and investor communication accuracy
- Engagement timeline
- Discovery 2 weeks → Build 8 weeks → Run continuous (4-week initial stabilization)
- Team size
- 1 senior delivery + 1 part-time integration eng
- Discovery price
- $8k · 2-3 week sprint
- Build price
- $30k–$40k · 8-12 weeks
Primary outcome
turn regulatory work into a traceable operating system
What we ship
policy assistant, evidence tracker, control library, and review workflow
KPIs we report on
audit readiness, control failure rate, review cycle time, and remediation backlog
Why Biotechnology teams hire us for this
What separates AI-native compliance operations from "AI features added on top" is operating discipline. The pattern that works in biotechnology is the same one that works for any high-stakes operational system: instrument the baseline, ship a thin slice to production, govern explicitly, then expand. We run every engagement against that pattern.
BIS and OECD guidance on AI in regulated sectors (including biotechnology) converges on a common requirement: explainable decisions, traceable inputs, versioned models. Our control stack is built against that requirement, not retrofitted.
Industry context: Mid-market and enterprise operators face the same fundamental tradeoff: AI must compress operational cycle time while remaining auditable and integrable with existing systems of record.
Benchmarks we hit
Reference benchmarks from production deployments of compliance operations in biotechnology-comparable contexts. Sources noted per row. Your actuals are measured against the baseline captured in Discovery.
| Metric | Industry baseline | AI-native typical | Delta |
|---|---|---|---|
Audit-log completeness Every inference call + reviewer action captured with version metadata | 62% | 100% | +38 pts |
Time-to-attestation Quarterly attestation packs assembled from audit log; reviewer signs off in hours | 21 days | 3 days | −86% |
Loss avoided / quarter (vs no AI) Conservative estimate; actuals depend on fraud volume + ticket size | $0 (no AI lift) | $280k median | Net positive |
Benchmarks are reference values from comparable engagements and authoritative sector benchmarks. Your engagement's baseline is captured during Discovery and actuals are reported weekly during Run against that baseline.
How we operate the workflow
The unit of operation on compliance operations is not a model call — it is a case (a ticket, a claim, a record, a request) that flows from intake to outcome. We instrument every case end-to-end: where it came in, what context it was matched against, what action was taken, who reviewed it, how long it took, whether the outcome held. For biotechnology teams, that case-level telemetry is what makes the workflow operationally legible.
What we build inside the workflow
The Build phase for compliance operations in biotechnology produces six tangible artefacts: a workflow map (current and target state), a labelled test set (200-1000 cases minimum), a prompt and retrieval repository (versioned, tested, deployed), the integration layer (against ELN and adjacent systems), the reviewer queue (with SLAs and escalation paths), and the operating dashboard (KPIs, drift detection, attestation pack). All six are inspectable, all six are handed over.
Reference architecture
4-layer AI-native workflow for risk & compliance
Source intake → AI orchestration → Action → Human review & quality.See the full architecture diagram for Risk & Compliance →
AI-native vs traditional approach
How a scoped AI-native engagement compares to the traditional alternatives for compliance operations in biotechnology.
| Dimension | Traditional (in-house build or BPO) | AI-native engagement (us) |
|---|---|---|
| Time to production | 6-12 months | 6-10 weeks (thin slice) |
| Pricing model | FTE hourly retainer or fixed staffing | Phased fixed-price (Discovery → Build → opt Run) |
| Audit / governance | Manual logs, periodic review | Versioned prompts, audit logs, reviewer queues, attestations |
| Operator throughput lift | 1.0× (baseline) | −86% |
| Cost per unit | Industry baseline | AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting. |
| Exit path | Multi-quarter notice + knowledge loss | Month-to-month Run, full handover plan in Build SoW |
Traditional process automation projects cost $80-200k+ with 6-12 month payback; AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting.
Engagement scope & pricing
We run this as a fixed-scope engagement with a clear commercial envelope, not an open-ended retainer.
Governed engagement
Three phases, billed separately. You commit one phase at a time.
Phase 1 · Discovery
$8k
2-3 week sprint
Phase 2 · Build
$30k–$40k
8-12 weeks
Phase 3 · Run
$4k–$6k / mo
optional, quarterly attestations available
~$52k–$90k typical year 1 (~80% take the run option, regulated workflows need ongoing controls)
Controls, audit logs, reviewer queues, versioned prompts, and quarterly risk attestations.
Discovery is the only commitment to start. After Discovery, we scope Build with a fixed price. Run is opt-in, month-to-month, no lock-in.
The 4-phase delivery model
Phase 1 · Weeks 1–2
Discovery
We map the workflow, the systems, the decisions, and the baseline metrics. Output: a scoped statement of work.
Phase 2 · Weeks 2–4
Design
We design the operating model: data access, retrieval, prompts, review queues, controls, and the KPI dashboard.
Phase 3 · Weeks 4–8
Build
We ship a production thin slice on real data, with versioned prompts, evaluation harness, and human review.
Phase 4 · Weeks 8+
Run
We run the workflow with you weekly, expand into adjacent work, and report against baseline.
Interactive ROI calculator
Estimate your AI-native ROI for compliance operations
Reference inputs below are typical for biotechnology teams in the risk compliance cluster. Adjust them to match your situation.
Projected
Current monthly cost
$57,000
AI-native monthly cost
$20,070
Annual savings
$443,160
65% cost reduction · ~656 operator-hours freed / month
Governance and risk controls
Internal auditors and external regulators in biotechnology converge on the same three questions: data provenance, decision traceability, replayability. Our control stack answers all three from the same audit log — one source of truth, queryable, exportable, signed. No spreadsheet reconciliation, no after-the-fact narrative.
How we report ROI
The business case lives in operating metrics, not model benchmarks. For compliance operations, the metrics that matter are audit readiness, control failure rate, review cycle time, and remediation backlog. For Biotechnology, leadership will also care about protocol cycle time, partner response time, experiment documentation quality, and BD pipeline velocity. Every build decision we make connects to one of those metrics, and we publish a weekly performance review during the Run phase.
Common pitfall & mitigation
The failure mode we see most often on AI-native compliance operations engagements in biotechnology contexts.
Regulator surprise at first attestation
Audit trail is incomplete; reviewer left a 3-week gap in week 4
Audit log designed as primary artifact (not log-as-afterthought); weekly attestation rehearsal
Build internally or work with us
Biotechnology teams that build successfully in-house tend to have an existing ML platform, a labelled data culture, and a product manager dedicated to the workflow. If any of those is missing, the project tends to stall at proof-of-concept. We replace those three dependencies with a scoped engagement and a senior delivery team.
What to ask us before signing
- Ask for a workflow map that shows intake, retrieval, generation, review, escalation, system updates, and measurement.
- Ask for an evaluation plan using real examples from biotechnology, not only generic test prompts.
- Ask how we will move audit readiness, control failure rate, review cycle time, and remediation backlog within the first 30 to 60 days.
- Ask which parts of the process remain human-owned and why.
- Ask for our exit plan: what stays with you if the engagement ends.
Recommended first project
The best first project for AI-native compliance operations in biotechnology is a contained workflow with enough volume to matter and enough structure to evaluate. Avoid the most politically sensitive process first. Avoid a workflow with no measurable baseline. Choose a process where we can ship a production-grade thin slice, prove adoption, and then extend the same architecture to neighboring work.
A practical target is a 30-day build followed by a 60-day operating period. In the first 30 days, we map the work, connect the minimum data sources, build the assistant, and create the review process. In the next 60 days, the system handles real volume, the team measures outcomes, and we improve the workflow weekly. By day 90, leadership knows whether to expand into adjacent work.
Frequently asked questions
How do you automate compliance operations in biotechnology with AI?+
We map the existing compliance operations workflow inside biotechnology, identify the high-volume, high-structure tasks, and build an AI agent that handles those tasks while routing low-confidence cases to a human reviewer. The build connects to your ELN, LIMS, clinical trial systems, runs against a labelled test set, and ships behind a reviewer queue before it sees production traffic. We then operate it, measure audit readiness, control failure rate, review cycle time, and remediation backlog, and improve it weekly.
What does it cost to automate compliance operations for a biotechnology company?+
Three phases, billed separately. Discovery sprint: $8k (2-3 week sprint). Build engagement: $30k–$40k (8-12 weeks). Run retainer: $4k–$6k / mo (optional, quarterly attestations available). ~$52k–$90k typical year 1 (~80% take the run option, regulated workflows need ongoing controls). Controls, audit logs, reviewer queues, versioned prompts, and quarterly risk attestations.
What is the best AI agent for compliance operations in biotechnology?+
There is no single "best" off-the-shelf agent for compliance operations in biotechnology — the right architecture depends on your ELN setup, your data, and your risk profile. We typically combine a frontier LLM (Claude, GPT-4-class, or Gemini) with a retrieval layer over your approved sources, tool-use for ELN and LIMS integrations, and a reviewer queue. We benchmark candidate models against a labelled test set during Discovery and pick the one with the best accuracy/cost ratio for your workflow.
How long does it take to deploy AI compliance operations for biotechnology?+
A thin-slice deployment in 2-3 week sprint after Discovery, with real biotechnology data and real reviewers. The full Build phase runs 8-12 weeks. By day 90, audit readiness, control failure rate, review cycle time, and remediation backlog is instrumented, the team has a baseline, and leadership has the data needed to decide on expansion into adjacent biotechnology workflows.
What do we own, and what do you own?+
We own the workflow design, the prompts, the retrieval architecture, the evaluation harness, and weekly improvement. Your biotech founders, clinical operations teams, business development leaders, and scientific program managers team owns data access, policy, exception approval, and final commercial decisions. At the end of the engagement, every prompt, eval, and config is handed over — no lock-in.
How do you handle risk and audit for AI compliance operations in biotechnology?+
Every output is grounded in approved sources, every prompt is versioned, and every reviewer action is logged. We provide a control map covering scientific validity, IP protection, trial documentation, privacy, and investor communication accuracy, plus quarterly attestations on request.
Sources we reference
The following sources inform the architecture, governance, and benchmarks we apply on biotechnology engagements. Cited here so you can verify and dig deeper.
- NIH Artificial Intelligence
- Hype Cycle for Artificial Intelligence — Gartner
- MIT Sloan Management Review — AI & Business Strategy — MIT Sloan
- Model Risk Management Handbook — Federal Reserve (SR 11-7)
- Principles for the Sound Management of AI Risks — BIS Financial Stability Institute
- Google Search Central: helpful, reliable, people-first content
- Google Search Central: URL structure best practices
Concepts on this page:
AI governance·NIST AI RMF·Audit log·Grounding·Guardrails·Model cardFull glossary →Start the engagement
Book a discovery call for Biotechnology
Tell us about your workflow, the systems involved, and the KPI you want to move. We'll send a scoped statement of work within 5 business days.